In a recently published phase-I, open label clinical trial, 50 patients with chronic HCV infection were treated orally with a combination of seven antioxidative oral preparations (glycyrrhizin, schisandra, silymarin, ascorbic acid, lipoic acid, L-glutathione, and alpha-tocopherol) on a daily basis for 20 weeks, along with four different intravenous preparations (glycyrrhizin, ascorbic acid, L-glutathione, B-complex) twice weekly for the first 10 wk[11]. Normalization of liver enzymes occurred in 44% of patients who had elevated pretreatment ALT levels. A decrease in viral load by one log or more was observed in 25% of the patients. Histological improvement, with twopoint reduction in the HAI score, was noted in 36.1% of the patients. The SF-36 quality of life score improved in 26 of 45 patients (58%) throughout the trial. No major adverse reactions were noted. These findings suggest that antioxidant therapy may have a beneficial effect on necroinflammatory variables in these patients.
Then they did this study:
http://www.wjgnet.com/1007-9327/13/5317.pdf( summary from abstract )